Challenges and opportunities in childhood cancer drug development.
Advances made in the treatment of childhood malignancies over the past four decades have resulted in overall 5-year survival rates of approximately 80%. However, despite these advances, several childhood cancers still have unacceptably low cure rates, and, even when treatment is successful, the acute and long-term morbidity of current therapy can be substantial. The development of molecularly targeted anticancer drugs offers the prospect of more effective therapy with fewer side effects, but will require increasing partnership between governments, and the academic and private sectors.
The Rainbow Babies and Children's Hospital, Pediatric Hematology/Oncology, Cleveland, Ohio 44106, USA. Robin.Norris@UHhospitals.org
Robin E
RE
Norris
Peter C
PC
Adamson
D000293:Adolescent; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D055808:Drug Discovery / Q000639:trends; D005544:Forecasting; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents